<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40693198</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>24</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-861X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Frontiers in nutrition</Title><ISOAbbreviation>Front Nutr</ISOAbbreviation></Journal><ArticleTitle>Effects of a polyphenol-rich extract blend, probiotics, and hydrolyzed fiber on quality of life and gut health markers in patients with irritable bowel syndrome-A randomized, double-blind, placebo-controlled trial.</ArticleTitle><Pagination><StartPage>1603011</StartPage><MedlinePgn>1603011</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1603011</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fnut.2025.1603011</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Irritable bowel syndrome (IBS) is the most prevalent functional bowel disorder impacting around 5%-10% of the general population worldwide. The pathogenesis remains unclear, however alterations in gut-brain axis play a critical role. We aimed to investigate the therapeutic potential of a novel synbiotic formulation comprising of partially hydrolyzed guar gum (PHGG), specific probiotic strains (<i>Bifidobacterium</i> and <i>Saccharomyces boulardii</i>), and double-standardized, polyphenol-rich blend of extracts from <i>Aronia melanocarpa</i> and <i>Sambucus nigra</i> in patients with IBS.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A total of 47 patients with IBS were randomly assigned to three groups and followed over a 2-month study period. Group I (<i>n</i> = 14) received placebo capsules, Group II (<i>n</i> = 14) took one placebo capsule along with a probiotic formulation and PHGG, Group III (<i>n</i> = 19) received probiotic formulation, PHGG and polyphenol-rich fruit extracts blend. The IBS-quality of life (QoL) questionnaire was completed by all participants at baseline and after 2 months. Serum levels of IL-6, IL-8, TNF-&#x3b1;, I-FABP-2, GM-CSF and stool concentrations of short-chain fatty acids (SCFAs) and zonulin were evaluated before and after intervention.</AbstractText><AbstractText Label="RESULTS AND CONCLUSIONS" NlmCategory="UNASSIGNED">This study demonstrated a significant improvement in QoL in individuals receiving the complete formulation combination (Group III). The largest decrease in score was observed in dysphoria, with median differences of -5 in Group III (<i>p</i> = 0.0021), -3 in Group II (<i>p</i> = 0.0155), and -1 in the control Group I (<i>p</i> = 0.0338). Significant correlations were found in Groups II and III between supplementation and serum concentrations of IL-8, TNF, and GM-CSF (<i>p</i> &lt; 0.05). A significantly higher concentration of all SCFAs was seen after intervention in Group III compared to control Group I.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Wierzbicka, Khaidakov, Zakerska-Banaszak, Andrzejewska, Baturo, Kowalczyk, Lemke, Dobrowolska, Skrzypczak-Zielinska and Mankowska-Wierzbicka.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wierzbicka</LastName><ForeName>Adrianna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Dietetics and Internal Diseases, Poznan University of Medical Sciences, Poznan, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Cleveland Clinic Florida, Weston, FL, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khaidakov</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>R&amp;D Department, AronPharma Ltd., Gda&#x144;sk, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zakerska-Banaszak</LastName><ForeName>Oliwia</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Institute of Human Genetics, Polish Academy of Sciences, Pozna&#x144;, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrzejewska</LastName><ForeName>Paulina</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>R&amp;D Department, AronPharma Ltd., Gda&#x144;sk, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baturo</LastName><ForeName>Alina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Dietetics and Internal Diseases, Poznan University of Medical Sciences, Poznan, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kowalczyk</LastName><ForeName>Paulina</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>3P-Medicine Laboratory, Medical University of Gda&#x144;sk, Gda&#x144;sk, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemke</LastName><ForeName>Krzysztof</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>R&amp;D Department, AronPharma Ltd., Gda&#x144;sk, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dobrowolska</LastName><ForeName>Agnieszka</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Dietetics and Internal Diseases, Poznan University of Medical Sciences, Poznan, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skrzypczak-Zielinska</LastName><ForeName>Marzena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Human Genetics, Polish Academy of Sciences, Pozna&#x144;, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mankowska-Wierzbicka</LastName><ForeName>Dorota</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Dietetics and Internal Diseases, Poznan University of Medical Sciences, Poznan, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Nutr</MedlineTA><NlmUniqueID>101642264</NlmUniqueID><ISSNLinking>2296-861X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FODMAP</Keyword><Keyword MajorTopicYN="N">SCFAs</Keyword><Keyword MajorTopicYN="N">dietary intervention</Keyword><Keyword MajorTopicYN="N">fiber</Keyword><Keyword MajorTopicYN="N">irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">polyphenols</Keyword><Keyword MajorTopicYN="N">probiotics</Keyword><Keyword MajorTopicYN="N">quality of life</Keyword></KeywordList><CoiStatement>BK, PK and KL have a patent for Fenactive&#xae; blend no. 245254 and a patent pending for Fenactive&#xae; blend no. P.437487. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>22</Day><Hour>4</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40693198</ArticleId><ArticleId IdType="pmc">PMC12277158</ArticleId><ArticleId IdType="doi">10.3389/fnut.2025.1603011</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mayer EA, Ryu HJ, Bhatt RR. The neurobiology of irritable bowel syndrome. Mol Psychiatry. (2023) 28:1451&#x2013;65. 10.1038/s41380-023-01972-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-023-01972-w</ArticleId><ArticleId IdType="pmc">PMC10208985</ArticleId><ArticleId IdType="pubmed">36732586</ArticleId></ArticleIdList></Reference><Reference><Citation>Palsson OS, Whitehead WE, Van Tilburg MAL, Chang L, Chey W, Crowell MD, et al. Development and validation of the Rome IV diagnostic questionnaire for adults. Gastroenterology. (2016) 150:1481&#x2013;91. 10.1053/j.gastro.2016.02.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.02.014</ArticleId><ArticleId IdType="pubmed">27144634</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol. (2016) 1:133&#x2013;46. 10.1016/S2468-1253(16)30023-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(16)30023-1</ArticleId><ArticleId IdType="pubmed">28404070</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Chey WD, Haller E, Eswaran S. Low-FODMAP diet for irritable bowel syndrome: what we know and what we have yet to learn. Annu Rev Med. (2020) 71:303&#x2013;14. 10.1146/annurev-med-050218-013625</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-med-050218-013625</ArticleId><ArticleId IdType="pubmed">31986083</ArticleId></ArticleIdList></Reference><Reference><Citation>Staudacher HM, Whelan K, Irving PM, Lomer MCE. Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome. J Human Nutrition Diet. (2011) 24:487&#x2013;95. 10.1111/j.1365-277X.2011.01162.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-277X.2011.01162.x</ArticleId><ArticleId IdType="pubmed">21615553</ArticleId></ArticleIdList></Reference><Reference><Citation>Black CJ, Staudacher HM, Ford AC. Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis. Gut. (2022) 71:1117&#x2013;26. 10.1136/gutjnl-2021-325214</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-325214</ArticleId><ArticleId IdType="pubmed">34376515</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma G, Bercik P. Long-term personalized low FODMAP diet in IBS. Neurogastroenterol Motil. (2022) 34:e14356. 10.1111/nmo.14356</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.14356</ArticleId><ArticleId IdType="pubmed">35293089</ArticleId></ArticleIdList></Reference><Reference><Citation>Varj&#xfa; P, Farkas N, Hegyi P, Garami A, Szab&#xf3; I, Ill&#xe9;s A, et al. Low fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet improves symptoms in adults suffering from irritable bowel syndrome (IBS) compared to standard IBS diet: a meta-analysis of clinical studies. PLoS ONE. (2017) 12:e0182942. 10.1371/journal.pone.0182942</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0182942</ArticleId><ArticleId IdType="pmc">PMC5555627</ArticleId><ArticleId IdType="pubmed">28806407</ArticleId></ArticleIdList></Reference><Reference><Citation>Ireton-Jones C. The low FODMAP diet: fundamental therapy in the management of irritable bowel syndrome. Curr Opin Clin Nutr Metab Care. (2017) 20:414&#x2013;9. 10.1097/MCO.0000000000000398</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCO.0000000000000398</ArticleId><ArticleId IdType="pubmed">28617710</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Lorenzo C, Colombo F, Biella S, Stockley C, Restani P. Polyphenols and human health: the role of bioavailability. Nutrients. (2021) 13:273. 10.3390/nu13010273</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13010273</ArticleId><ArticleId IdType="pmc">PMC7833401</ArticleId><ArticleId IdType="pubmed">33477894</ArticleId></ArticleIdList></Reference><Reference><Citation>Niv E, Halak A, Tiommny E, Yanai H, Strul H, Naftali T, et al. Randomized clinical study: Partially hydrolyzed guar gum (PHGG) versus placebo in the treatment of patients with irritable bowel syndrome. Nutr Metab. (2016) 13:10. 10.1186/s12986-016-0070-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12986-016-0070-5</ArticleId><ArticleId IdType="pmc">PMC4744437</ArticleId><ArticleId IdType="pubmed">26855665</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams NT. Probiotics. Am J Health Syst Pharm. (2010) 67:449&#x2013;58. 10.2146/ajhp090168</Citation><ArticleIdList><ArticleId IdType="doi">10.2146/ajhp090168</ArticleId><ArticleId IdType="pubmed">20208051</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrae DA, Patrick DL, Drossman DA, Covington PS. Evaluation of the irritable bowel syndrome quality of life (IBS-QOL) questionnaire in diarrheal-predominant irritable bowel syndrome patients. Health Qual Life Outcomes. (2013) 11:208. 10.1186/1477-7525-11-208</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1477-7525-11-208</ArticleId><ArticleId IdType="pmc">PMC3895767</ArticleId><ArticleId IdType="pubmed">24330412</ArticleId></ArticleIdList></Reference><Reference><Citation>Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology. (2000) 119:654&#x2013;60. 10.1053/gast.2000.16484</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/gast.2000.16484</ArticleId><ArticleId IdType="pubmed">10982758</ArticleId></ArticleIdList></Reference><Reference><Citation>Linsalata M, Riezzo G, D'Attoma B, Clemente C, Orlando A, Russo F. Noninvasive biomarkers of gut barrier function identify two subtypes of patients suffering from diarrhoea predominant-IBS: a case-control study. BMC Gastroenterol. (2018) 18:167. 10.1186/s12876-018-0888-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12876-018-0888-6</ArticleId><ArticleId IdType="pmc">PMC6219148</ArticleId><ArticleId IdType="pubmed">30400824</ArticleId></ArticleIdList></Reference><Reference><Citation>Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev. (2011) 91:151&#x2013;75. 10.1152/physrev.00003.2008</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00003.2008</ArticleId><ArticleId IdType="pubmed">21248165</ArticleId></ArticleIdList></Reference><Reference><Citation>Vork L, Weerts ZZRM, Mujagic Z, Kruimel JW, Hesselink MAM, Muris JWM, et al. Rome III vs Rome IV criteria for irritable bowel syndrome: a comparison of clinical characteristics in a large cohort study. Neurogastroenterol Motil. (2018) 30:e13189. 10.1111/nmo.13189</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.13189</ArticleId><ArticleId IdType="pubmed">28804974</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheffler L, Crane A, Heyne H, T&#xf6;njes A, Schleinitz D, Ihling CH, et al. Widely used commercial ELISA does not detect precursor of haptoglobin2, but recognizes properdin as a potential second member of the zonulin family. Front Endocrinol. (2018) 9:22. 10.3389/fendo.2018.00022</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2018.00022</ArticleId><ArticleId IdType="pmc">PMC5807381</ArticleId><ArticleId IdType="pubmed">29459849</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao X, Cao Q, Cheng Y, Zhao D, Wang Z, Yang H, et al. Chronic stress promotes colitis by disturbing the gut microbiota and triggering immune system response. Proc Natl Acad Sci U S A. (2018) 115:E4542. 10.1073/pnas.1806622115</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1806622115</ArticleId><ArticleId IdType="pmc">PMC5879702</ArticleId><ArticleId IdType="pubmed">29531080</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Wang Z, Wang G, Song X, Qian Y, Liao Z, et al. Understanding the connection between gut homeostasis and psychological stress. J Nutr. (2023) 153:924&#x2013;39. 10.1016/j.tjnut.2023.01.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tjnut.2023.01.026</ArticleId><ArticleId IdType="pubmed">36806451</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamani M, Alizadeh-Tabari S, Zamani V. Systematic review with meta-analysis: the prevalence of anxiety and depression in patients with irritable bowel syndrome. Aliment Pharmacol Ther. (2019) 50:132&#x2013;43. 10.1111/apt.15325</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15325</ArticleId><ArticleId IdType="pubmed">31157418</ArticleId></ArticleIdList></Reference><Reference><Citation>Martoni CJ, Srivastava S, Leyer GJ. <i>Lactobacillus acidophilus</i> DDS-1 and <i>bifidobacterium lactis</i> UABla-12 improve abdominal pain severity and symptomology in irritable bowel syndrome: randomized controlled trial. Nutrients. (2020) 12:363. 10.3390/nu12020363
</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12020363</ArticleId><ArticleId IdType="pmc">PMC7071206</ArticleId><ArticleId IdType="pubmed">32019158</ArticleId></ArticleIdList></Reference><Reference><Citation>Waller PA, Gopal PK, Leyer GJ, Ouwehand AC, Reifer C, Stewart ME, et al. Dose-response effect of <i>Bifidobacterium lactis</i> HN019 on whole gut transit time and functional gastrointestinal symptoms in adults. Scand J Gastroenterol. (2011) 46:1057&#x2013;64. 10.3109/00365521.2011.584895
</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365521.2011.584895</ArticleId><ArticleId IdType="pmc">PMC3171707</ArticleId><ArticleId IdType="pubmed">21663486</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng J, Laitila A, Ouwehand AC. Bifidobacterium animalis subsp. <i>lactis</i> HN019 effects on gut health: a review. Front Nutr. (2021) 8:790561. 10.3389/fnut.2021.790561
</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnut.2021.790561</ArticleId><ArticleId IdType="pmc">PMC8712437</ArticleId><ArticleId IdType="pubmed">34970580</ArticleId></ArticleIdList></Reference><Reference><Citation>Airaksinen K, Yeung N, Lyra A, Lahtinen SJ, Huttunen T, Shanahan F, et al. The effect of a probiotic blend on gastrointestinal symptoms in constipated patients: a double blind, randomised, placebo controlled 2-week trial. Benef Microbes. (2019) 10:617&#x2013;28. 10.3920/BM2018.0163</Citation><ArticleIdList><ArticleId IdType="doi">10.3920/BM2018.0163</ArticleId><ArticleId IdType="pubmed">31131616</ArticleId></ArticleIdList></Reference><Reference><Citation>Pokusaeva K, Fitzgerald GF, Van Sinderen D. Carbohydrate metabolism in Bifidobacteria. Genes Nutr. (2011) 6:285&#x2013;306. 10.1007/s12263-010-0206-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12263-010-0206-6</ArticleId><ArticleId IdType="pmc">PMC3145055</ArticleId><ArticleId IdType="pubmed">21484167</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal A, Houghton LA, Morris J, Reilly B, Guyonnet D, Goupil Feuillerat N, et al. Clinical trial: the effects of a fermented milk product containing <i>Bifidobacterium lactis</i> DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther. (2009) 29:104&#x2013;14. 10.1111/j.1365-2036.2008.03853.x
</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2008.03853.x</ArticleId><ArticleId IdType="pubmed">18801055</ArticleId></ArticleIdList></Reference><Reference><Citation>Brun P, Scarpa M, Marchiori C, Sarasin G, Caputi V, Porzionato A, et al. Saccharomyces boulardii CNCM I-745 supplementation reduces gastrointestinal dysfunction in an animal model of IBS. PLoS ONE. (2017) 12:e0181863. 10.1371/journal.pone.0181863</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0181863</ArticleId><ArticleId IdType="pmc">PMC5521842</ArticleId><ArticleId IdType="pubmed">28732069</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Y, Wang C, Qin X, Zhou B, Liu X, Liu T, et al. <i>Saccharomyces boulardii</i>, a yeast probiotic, inhibits gut motility through upregulating intestinal serotonin transporter and modulating gut microbiota. Pharmacol Res. (2022) 181:106291. 10.1016/j.phrs.2022.106291
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2022.106291</ArticleId><ArticleId IdType="pubmed">35690329</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkinson W, Lockhart S, Whorwell PJ, Keevil B, Houghton LA. Altered 5-Hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology. (2006) 130:34&#x2013;43. 10.1053/j.gastro.2005.09.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2005.09.031</ArticleId><ArticleId IdType="pubmed">16401466</ArticleId></ArticleIdList></Reference><Reference><Citation>Parisi G, Bottona E, Carrara M, Cardin F, Faedo A, Goldin D, et al. Treatment effects of partially hydrolyzed guar gum on symptoms and quality of life of patients with irritable bowel syndrome. A Multicenter Randomized Open Trial. Dig Dis Sci. (2005) 50:1107&#x2013;12. 10.1007/s10620-005-2713-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-005-2713-7</ArticleId><ArticleId IdType="pubmed">15986863</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuohy KM, Kolida S, Lustenberger AM, Gibson GR. The prebiotic effects of biscuits containing partially hydrolysed guar gum and fructo-oligosaccharides &#x2013; a human volunteer study. Br J Nutr. (2001) 86:341&#x2013;8. 10.1079/BJN2001394</Citation><ArticleIdList><ArticleId IdType="doi">10.1079/BJN2001394</ArticleId><ArticleId IdType="pubmed">11570986</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki D, Sasaki K, Abe A, Ozeki M, Kondo A. Effects of partially hydrolyzed guar gums of different molecular weights on a human intestinal <i>in vitro</i> fermentation model. J Biosci Bioeng. (2023) 136:67&#x2013;73. 10.1016/j.jbiosc.2023.04.002
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbiosc.2023.04.002</ArticleId><ArticleId IdType="pubmed">37105857</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannini EG, Mansi C, Dulbecco P, Savarino V. Role of partially hydrolyzed guar gum in the treatment of irritable bowel syndrome. Nutrition. (2006) 22:334&#x2013;42. 10.1016/j.nut.2005.10.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nut.2005.10.003</ArticleId><ArticleId IdType="pubmed">16413751</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohashi Y, Sumitani K, Tokunaga M, Ishihara N, Okubo T, Fujisawa T. Consumption of partially hydrolysed guar gum stimulates Bifidobacteria and butyrate-producing bacteria in the human large intestine. Benef Microbes. (2015) 6:451&#x2013;6. 10.3920/BM2014.0118</Citation><ArticleIdList><ArticleId IdType="doi">10.3920/BM2014.0118</ArticleId><ArticleId IdType="pubmed">25519526</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson J, Gould T, Slavin J. <i>In vitro</i> analysis of partially hydrolyzed guar gum fermentation on identified gut microbiota. Anaerobe. (2016) 42:60&#x2013;6. 10.1016/j.anaerobe.2016.08.006
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.anaerobe.2016.08.006</ArticleId><ArticleId IdType="pubmed">27585552</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-S&#xe1;nchez C, Escudero-L&#xf3;pez B, Fern&#xe1;ndez-Pach&#xf3;n MS. Evaluation of the efficacy of probiotics as treatment in irritable bowel syndrome. Endocrinolog&#xed;a, Diabetes y Nutr. (2024) 71:19&#x2013;30. 10.1016/j.endien.2024.01.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.endien.2024.01.003</ArticleId><ArticleId IdType="pubmed">38331656</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin-Gallausiaux C, Marinelli L, Blotti&#xe8;re HM, Larraufie P, Lapaque N. SCFA: mechanisms and functional importance in the gut. Proc Nutr Soc. (2021) 80:37&#x2013;49. 10.1017/S0029665120006916</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0029665120006916</ArticleId><ArticleId IdType="pubmed">32238208</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogdanovic A, Borlotti Amico B, Dainelli L, Furneri G. Economic analysis of partially hydrolyzed guar gum (PHGG) for the treatment of patients receiving enteral nutrition. Clin Nutr Open Sci. (2024) 53:11&#x2013;24. 10.1016/j.nutos.2023.11.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nutos.2023.11.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Y, Frank T, Meyer G, Lei J, Grebenc JR, Slaughter R, et al. Potential benefits of black chokeberry (<i>Aronia melanocarpa</i>) fruits and their constituents in improving human health. Molecules. (2022) 27:7823. 10.3390/molecules27227823
</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27227823</ArticleId><ArticleId IdType="pmc">PMC9696386</ArticleId><ArticleId IdType="pubmed">36431924</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Nguepi Tsopmejio IS, Diao Z, Xiao H, Wang X, Jin Z, et al. <i>Aronia melanocarpa</i> (Michx) Elliott attenuates dextran sulfate sodium-induced inflammatory bowel disease via regulation of inflammation-related signaling pathways and modulation of the gut microbiota. J Ethnopharmacol. (2022) 292:115190. 10.1016/j.jep.2022.115190
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2022.115190</ArticleId><ArticleId IdType="pubmed">35306040</ArticleId></ArticleIdList></Reference><Reference><Citation>Valcheva-Kuzmanova S, Kuzmanov A, Kuzmanova V, Tzaneva M. Aronia melanocarpa fruit juice ameliorates the symptoms of inflammatory bowel disease in TNBS-induced colitis in rats. Food Chem Toxicol. (2018) 113:33&#x2013;9. 10.1016/j.fct.2018.01.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fct.2018.01.011</ArticleId><ArticleId IdType="pubmed">29331733</ArticleId></ArticleIdList></Reference><Reference><Citation>Olejnik A, Kowalska K, Olkowicz M, Rychlik J, Juzwa W, Myszka K, et al. Anti-inflammatory effects of gastrointestinal digested <i>Sambucus nigra</i> L. fruit extract analysed in co-cultured intestinal epithelial cells and lipopolysaccharide-stimulated macrophages. J Funct Foods. (2015) 19:649&#x2013;60. 10.1016/j.jff.2015.09.064</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jff.2015.09.064</ArticleId></ArticleIdList></Reference><Reference><Citation>Namakin K, Moghaddam MH, Sadeghzadeh S, Mehranpour M, Vakili K, Fathi M, et al. Elderberry diet improves gut-brain axis dysfunction, neuroinflammation, and cognitive impairment in the rat model of irritable bowel syndrome. Metab Brain Dis. (2023) 38:1555&#x2013;72. 10.1007/s11011-023-01187-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11011-023-01187-6</ArticleId><ArticleId IdType="pubmed">36877342</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro MM, Santos Z, Carolino E, Correa J, Cravo M, Augusto F, et al. Effectiveness of two dietary approaches on the quality of life and gastrointestinal symptoms of individuals with irritable bowel syndrome. J Clin Med. (2020) 9:125. 10.3390/jcm9010125</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9010125</ArticleId><ArticleId IdType="pmc">PMC7019629</ArticleId><ArticleId IdType="pubmed">31906563</ArticleId></ArticleIdList></Reference><Reference><Citation>Naseri K, Dabiri H, Rostami-Nejad M, Yadegar A, Houri H, Olfatifar M, et al. Influence of low FODMAP-gluten free diet on gut microbiota alterations and symptom severity in Iranian patients with irritable bowel syndrome. BMC Gastroenterol. (2021) 21:292. 10.1186/s12876-021-01868-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12876-021-01868-5</ArticleId><ArticleId IdType="pmc">PMC8278734</ArticleId><ArticleId IdType="pubmed">34261437</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie CR, Tang B, Shi YZ, Peng WY, Ye K, Tao QF, et al. Low FODMAP diet and probiotics in irritable bowel syndrome: a systematic review with network meta-analysis. Front Pharmacol. (2022) 13:853011. 10.3389/fphar.2022.853011</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.853011</ArticleId><ArticleId IdType="pmc">PMC8959572</ArticleId><ArticleId IdType="pubmed">35355730</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong Z, Mok C, Majid HA, Mahadeva S. Early experience with a low FODMAP diet in Asian patients with irritable bowel syndrome. JGH Open. (2018) 2:178&#x2013;81. 10.1002/jgh3.12069</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jgh3.12069</ArticleId><ArticleId IdType="pmc">PMC6207042</ArticleId><ArticleId IdType="pubmed">30483586</ArticleId></ArticleIdList></Reference><Reference><Citation>Ankersen DV, Weimers P, Bennedsen M, Haaber AB, Fjordside EL, Beber ME, et al. Long-term effects of a web-based low-FODMAP diet versus probiotic treatment for irritable bowel syndrome, including shotgun analyses of microbiota: randomized, double-crossover clinical trial. J Med Internet Res. (2021) 23:e30291. 10.2196/30291</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/30291</ArticleId><ArticleId IdType="pmc">PMC8715363</ArticleId><ArticleId IdType="pubmed">34904950</ArticleId></ArticleIdList></Reference><Reference><Citation>Hustoft TN, Hausken T, Ystad SO, Valeur J, Brokstad K, Hatlebakk JG, et al. Effects of varying dietary content of fermentable short-chain carbohydrates on symptoms, fecal microenvironment, and cytokine profiles in patients with irritable bowel syndrome. Neurogastroenterol Motil. (2017) 29:e12969. 10.1111/nmo.12969</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.12969</ArticleId><ArticleId IdType="pubmed">27747984</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf6;hn L, St&#xf6;rsrud S, Liljebo T, Collin L, Lindfors P, T&#xf6;rnblom H, et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology. (2015) 149:1399&#x2013;407.e2. 10.1053/j.gastro.2015.07.054</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2015.07.054</ArticleId><ArticleId IdType="pubmed">26255043</ArticleId></ArticleIdList></Reference><Reference><Citation>Conley TE, Slater R, Moss S, Bulmer DC, Negro JDLR, Ijaz UZ, et al. Microbiome-driven IBS metabotypes influence response to the low FODMAP diet: insights from the faecal volatome. EBioMedicine. (2024) 107:105282. 10.1016/j.ebiom.2024.105282</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2024.105282</ArticleId><ArticleId IdType="pmc">PMC11388012</ArticleId><ArticleId IdType="pubmed">39173527</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta Mol Cell Res. (2011) 1813:878&#x2013;88. 10.1016/j.bbamcr.2011.01.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2011.01.034</ArticleId><ArticleId IdType="pubmed">21296109</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang MJ, Zhang HL, Chen F, Guo XJ, Liu QG, Hou J. The double-edged effects of IL-6 in liver regeneration, aging, inflammation, and diseases. Exp Hematol Oncol. (2024) 13:62. 10.1186/s40164-024-00527-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40164-024-00527-1</ArticleId><ArticleId IdType="pmc">PMC11184755</ArticleId><ArticleId IdType="pubmed">38890694</ArticleId></ArticleIdList></Reference><Reference><Citation>Alhendi A, Naser SA. The dual role of interleukin-6 in Crohn's disease pathophysiology. Front Immunol. (2023) 14:1295230. 10.3389/fimmu.2023.1295230</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1295230</ArticleId><ArticleId IdType="pmc">PMC10722226</ArticleId><ArticleId IdType="pubmed">38106420</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn KA, Manieri NA, Liu TC, Stappenbeck TS. IL-6 stimulates intestinal epithelial proliferation and repair after injury. PLoS ONE. (2014) 9:e114195. 10.1371/journal.pone.0114195</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0114195</ArticleId><ArticleId IdType="pmc">PMC4257684</ArticleId><ArticleId IdType="pubmed">25478789</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch AE, Volin MV, Woods JM, Kunkel SL, Connors MA, Harlow LA, et al. Regulation of angiogenesis by the C-X-C chemokines interleukin-8 and epithelial neutrophil activating peptide 78 in the rheumatoid joint. Arthritis Rheum. (2001) 44:31&#x2013;40. 10.1002/1529-0131(200101)44:1&lt;31::AID-ANR5&gt;3.0.CO;2-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1529-0131(200101)44:1&lt;31::AID-ANR5&gt;3.0.CO;2-4</ArticleId><ArticleId IdType="pubmed">11212173</ArticleId></ArticleIdList></Reference><Reference><Citation>Gimbrone MA, Obin MS, Brock AF, Luis EA, Hass PE, H&#xe9;bert CA, et al. Endothelial interleukin-8: a novel inhibitor of leukocyte-endothelial interactions. Science. (1989) 246:1601&#x2013;3. 10.1126/science.2688092</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.2688092</ArticleId><ArticleId IdType="pubmed">2688092</ArticleId></ArticleIdList></Reference><Reference><Citation>Maheshwari A, Lu W, Lacson A, Barleycorn AA, Nolan S, Christensen RD, et al. Effects of interleukin-8 on the developing human intestine. Cytokine. (2002) 20:256&#x2013;67. 10.1006/cyto.2002.1996</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/cyto.2002.1996</ArticleId><ArticleId IdType="pubmed">12633567</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucharzik T. Acute induction of human IL-8 production by intestinal epithelium triggers neutrophil infiltration without mucosal injury. Gut. (2005) 54:1565&#x2013;72. 10.1136/gut.2004.061168</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2004.061168</ArticleId><ArticleId IdType="pmc">PMC1774758</ArticleId><ArticleId IdType="pubmed">15987794</ArticleId></ArticleIdList></Reference><Reference><Citation>Szabady RL, McCormick BA. Control of neutrophil inflammation at mucosal surfaces by secreted epithelial products. Front Immunol. (2013) 4:220. 10.3389/fimmu.2013.00220</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2013.00220</ArticleId><ArticleId IdType="pmc">PMC3728559</ArticleId><ArticleId IdType="pubmed">23914188</ArticleId></ArticleIdList></Reference><Reference><Citation>Norlin AK, Walter S, Icenhour A, Keita &#xc5;V, Elsenbruch S, Bednarska O, et al. Fatigue in irritable bowel syndrome is associated with plasma levels of TNF-&#x3b1; and mesocorticolimbic connectivity. Brain Behav Immun. (2021) 92:211&#x2013;20. 10.1016/j.bbi.2020.11.035</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.11.035</ArticleId><ArticleId IdType="pubmed">33249172</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbas Z, Yakoob J, Jafri W, Ahmad Z, Azam Z, Usman MW, et al. Cytokine and clinical response to <i>Saccharomyces boulardii</i> therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial. Eur J Gastroenterol Hepatol. (2014) 26:630&#x2013;9. 10.1097/MEG.0000000000000094
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MEG.0000000000000094</ArticleId><ArticleId IdType="pubmed">24722560</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Liu M, Liu X, Zhong W, Li Y, Ran Y, et al. <i>Bifidobacterium animalis</i> ssp. lactis 420 mitigates autoimmune hepatitis through regulating intestinal barrier and liver immune cells. Front Immunol. (2020) 11:569104. 10.3389/fimmu.2020.569104
</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.569104</ArticleId><ArticleId IdType="pmc">PMC7573389</ArticleId><ArticleId IdType="pubmed">33123141</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokogawa YI, Oyanagi E, Aoki T, Watanabe C, Miura S, Kremenik MJ, et al. LPS-induced TNF-&#x3b1; production is attenuated by intake with PHGG via gut microbial fermentation in mice. Nutrition. (2022) 101:111705. 10.1016/j.nut.2022.111705</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nut.2022.111705</ArticleId><ArticleId IdType="pubmed">35660499</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro-Dopico T, Fleming A, Dennison TW, Ferdinand JR, Harcourt K, Stewart BJ, et al. GM-CSF calibrates macrophage defense and wound healing programs during intestinal infection and inflammation. Cell Rep. (2020) 32:107857. 10.1016/j.celrep.2020.107857</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.107857</ArticleId><ArticleId IdType="pmc">PMC7351110</ArticleId><ArticleId IdType="pubmed">32640223</ArticleId></ArticleIdList></Reference><Reference><Citation>Stier H, Bischoff S. Influence of <i>Saccharomyces boulardii</i> CNCM I-745 on the gut-associated immune system. Clin Exp Gastroenterol. (2016) 9:269&#x2013;79. 10.2147/CEG.S111003
</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CEG.S111003</ArticleId><ArticleId IdType="pmc">PMC5027949</ArticleId><ArticleId IdType="pubmed">27695355</ArticleId></ArticleIdList></Reference><Reference><Citation>Badia R, Zanello G, Chevaleyre C, Lizardo R, Meurens F, Martinez P, et al. Effect of <i>Saccharomyces cerevisiae</i> var. Boulardii and beta-galactomannan oligosaccharide on porcine intestinal epithelial and dendritic cells challenged <i>in vitro</i> with <i>Escherichia coli</i> F4 (K88). Vet Res. (2012) 43:4. 10.1186/1297-9716-43-4
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1297-9716-43-4</ArticleId><ArticleId IdType="pmc">PMC3305624</ArticleId><ArticleId IdType="pubmed">22277078</ArticleId></ArticleIdList></Reference><Reference><Citation>Mourey F, Decherf A, Jeanne JF, Cl&#xe9;ment-Ziza M, Grisoni ML, Machuron F, et al. <i>Saccharomyces cerevisiae</i> I-3856 in irritable bowel syndrome with predominant constipation. World J Gastroenterol. (2022) 28:2509&#x2013;22. 10.3748/wjg.v28.i22.2509
</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v28.i22.2509</ArticleId><ArticleId IdType="pmc">PMC9258277</ArticleId><ArticleId IdType="pubmed">35979259</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuck CJ, Caminero A, Jim&#xe9;nez Vargas NN, Soltys CL, Jaramillo Polanco JO, Lopez Lopez CD, et al. The impact of dietary fermentable carbohydrates on a postinflammatory model of irritable bowel syndrome. Neurogastroenterology Motil. (2019) 31:e13675. 10.1111/nmo.13675</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.13675</ArticleId><ArticleId IdType="pubmed">31290223</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L. The role of short-chain fatty acids in health and disease. Adv Immunol. (2014) 121:91&#x2013;119. 10.1016/B978-0-12-800100-4.00003-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-800100-4.00003-9</ArticleId><ArticleId IdType="pubmed">24388214</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook, Sellin. Review article: short chain fatty acids in health and disease. Aliment Pharmacol Ther. (1998) 12:499&#x2013;507. 10.1046/j.1365-2036.1998.00337.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.1998.00337.x</ArticleId><ArticleId IdType="pubmed">9678808</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaak EE, Canfora EE, Theis S, Frost G, Groen AK, Mithieux G, et al. Short chain fatty acids in human gut and metabolic health. Benef Microbes. (2020) 11:411&#x2013;55. 10.3920/BM2020.0057</Citation><ArticleIdList><ArticleId IdType="doi">10.3920/BM2020.0057</ArticleId><ArticleId IdType="pubmed">32865024</ArticleId></ArticleIdList></Reference><Reference><Citation>Burger-van Paassen N, Vincent A, Puiman PJ, van der Sluis M, Bouma J, Boehm G, et al. The regulation of intestinal mucin MUC2 expression by short-chain fatty acids: implications for epithelial protection. Biochem J. (2009) 420:211&#x2013;9. 10.1042/BJ20082222</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BJ20082222</ArticleId><ArticleId IdType="pubmed">19228118</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurst NR, Kendig DM, Murthy KS, Grider JR. The short chain fatty acids, butyrate and propionate, have differential effects on the motility of the guinea pig colon. Neurogastroenterol Motil. (2014) 26:1586&#x2013;96. 10.1111/nmo.12425</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.12425</ArticleId><ArticleId IdType="pmc">PMC4438679</ArticleId><ArticleId IdType="pubmed">25223619</ArticleId></ArticleIdList></Reference><Reference><Citation>So D, Loughman A, Staudacher HM. Effects of a low FODMAP diet on the colonic microbiome in irritable bowel syndrome: a systematic review with meta-analysis. Am J Clin Nutr. (2022) 116:943&#x2013;52. 10.1093/ajcn/nqac176</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcn/nqac176</ArticleId><ArticleId IdType="pmc">PMC9535515</ArticleId><ArticleId IdType="pubmed">35728042</ArticleId></ArticleIdList></Reference><Reference><Citation>Almutairi R, Basson AR, Wearsh P, Cominelli F, Rodriguez-Palacios A. Validity of food additive maltodextrin as placebo and effects on human gut physiology: systematic review of placebo-controlled clinical trials. Eur J Nutr. (2022) 61:2853&#x2013;71. 10.1007/s00394-022-02802-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00394-022-02802-5</ArticleId><ArticleId IdType="pmc">PMC9835112</ArticleId><ArticleId IdType="pubmed">35230477</ArticleId></ArticleIdList></Reference><Reference><Citation>Chadwick VS, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology. (2002) 122:1778&#x2013;83. 10.1053/gast.2002.33579</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/gast.2002.33579</ArticleId><ArticleId IdType="pubmed">12055584</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. (2004) 126:693&#x2013;702. 10.1053/j.gastro.2003.11.055</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2003.11.055</ArticleId><ArticleId IdType="pubmed">14988823</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>